Analysts See $-0.39 EPS for Corium International, Inc. (CORI)

July 11, 2018 - By Robert Shackelford

Investors sentiment decreased to 1.32 in 2018 Q1. Its down 0.47, from 1.79 in 2017Q4. It turned negative, as 7 investors sold Corium International, Inc. shares while 18 reduced holdings. 14 funds opened positions while 19 raised stakes. 32.85 million shares or 6.87% more from 30.74 million shares in 2017Q4 were reported.
Citigroup holds 2,409 shares or 0% of its portfolio. Veritable Lp has invested 0.01% in Corium International, Inc. (NASDAQ:CORI). Iguana Health Management Ltd Llc reported 110,000 shares. Kazazian Asset Mngmt Ltd Liability Corporation holds 19,518 shares. Rhumbline Advisers invested in 0% or 19,356 shares. Moreover, Deutsche Bancorp Ag has 0% invested in Corium International, Inc. (NASDAQ:CORI). Prelude Cap Management Llc has 0.02% invested in Corium International, Inc. (NASDAQ:CORI) for 28,808 shares. Barclays Public Limited holds 0% in Corium International, Inc. (NASDAQ:CORI) or 6,848 shares. Essex Mgmt Ltd Company holds 0.25% or 164,787 shares. Moreover, Gp has 0% invested in Corium International, Inc. (NASDAQ:CORI). Blackrock Incorporated owns 1.88M shares for 0% of their portfolio. Geode Ltd Limited Liability Company has invested 0% of its portfolio in Corium International, Inc. (NASDAQ:CORI). State Board Of Administration Of Florida Retirement Sys, Florida-based fund reported 12,065 shares. Morgan Stanley invested in 0% or 46,660 shares. Tiaa Cref Investment Llc reported 56,648 shares.

Analysts expect Corium International, Inc. (NASDAQ:CORI) to report $-0.39 EPS on August, 2.They anticipate $0.04 EPS change or 9.30 % from last quarter’s $-0.43 EPS. After having $-0.50 EPS previously, Corium International, Inc.’s analysts see -22.00 % EPS growth. The stock increased 3.12% or $0.24 during the last trading session, reaching $7.94. About 186,325 shares traded. Corium International, Inc. (NASDAQ:CORI) has risen 23.07% since July 12, 2017 and is uptrending. It has outperformed by 10.50% the S&P500.

Corium International, Inc. (NASDAQ:CORI) Ratings Coverage

Among 2 analysts covering Corium (NASDAQ:CORI), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Corium had 7 analyst reports since February 9, 2018 according to SRatingsIntel. The rating was maintained by H.C. Wainwright on Friday, February 9 with “Buy”. On Tuesday, March 27 the stock rating was maintained by Cantor Fitzgerald with “Buy”. Cantor Fitzgerald maintained Corium International, Inc. (NASDAQ:CORI) rating on Friday, February 9. Cantor Fitzgerald has “Buy” rating and $14.0 target. Cantor Fitzgerald maintained it with “Buy” rating and $1400 target in Monday, May 14 report. As per Thursday, March 8, the company rating was maintained by Cantor Fitzgerald. The company was maintained on Friday, June 15 by H.C. Wainwright. H.C. Wainwright maintained Corium International, Inc. (NASDAQ:CORI) rating on Tuesday, May 15. H.C. Wainwright has “Buy” rating and $1400 target.

Corium International, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. The company has market cap of $287.77 million. It offers Clonidine Transdermal Delivery System , a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening. It currently has negative earnings. The company??s products under pipeline comprise Twirla, a combination hormonal contraceptive patch, which has completed Phase III clinical trials to deliver ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system that has completed Phase 1 and Phase II a clinical trials for the treatment of severe osteoporosis; and Donepezil and Memantine transdermal systems, which completed Phase I clinical trials for the treatment of Alzheimer's disease.

More important recent Corium International, Inc. (NASDAQ:CORI) news were published by: which released: “Corium Announces Issuance of Key US Patent Covering Corplexâ„¢ Donepezil Transdermal System for Alzheimer’s …” on June 13, 2018, also published article titled: “Corium Announces Issuance of Additional US Patent Covering Corplexâ„¢ Donepezil Transdermal System for …”, published: “Corium Announces Issuance of Key US Patent Covering Corplex Donepezil Transdermal System for Alzheimer’s Disease” on June 13, 2018. More interesting news about Corium International, Inc. (NASDAQ:CORI) was released by: and their article: “An Update On Corium International” with publication date: June 15, 2018.

Corium International, Inc. (NASDAQ:CORI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.